Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study

Abstract

Treatment and survival of lymphoid malignancy in the north-west of England: a population-based study JHAM

The clinical impact of expert pathological review on lymphoma management: a regional experience

“…A number of published regional lymphoma review series have identified discrepancy rates of between 24% and 48% (Bird et al, 1984;Dick et al, 1987;Youngson et al, 1995). More recently, a comparative review of lymphomas submitted to a San Francisco community hospital identified a 11% discrepancy rate (Siebert et al, 2001).…”

“…When lymphoma pathology is reviewed by specialist haematopathologists, discrepancy rates of 24-48% between submitted and review diagnoses have been described (Bird et al, 1984;Dick et al, 1987;Youngson et al, 1995). A previous study by the AWLP identified a discrepancy rate of 20% in the 412 pathological specimens submitted for specialist review between January 1998 and January 2000 (Dojcinov & Attanoos, 2001).…”

“…A total of 53 consultant pathologists in 16 district general hospitals serving a population of 2AE9 million people participate in the review scheme. The review provides a primary diagnostic service where the diagnosis is unknown and a central pathological review of lymphomas where the primary diagnosis was made at the district general hospital by the general histopathologist.For the purposes of diagnostic standardization, the AWLP initially adopted the Revised European-American classification of Lymphoid neoplasms (REAL, Harris et al, 1994) and subsequently the World Health Organization (WHO) classification (Jaffe et al, 2001).When lymphoma pathology is reviewed by specialist haematopathologists, discrepancy rates of 24-48% between submitted and review diagnoses have been described (Bird et al, 1984;Dick et al, 1987;Youngson et al, 1995). A previous study by the AWLP identified a discrepancy rate of 20% in the 412 pathological specimens submitted for specialist review between January 1998 and January 2000 (Dojcinov & Attanoos, 2001).…”

Reovirus therapy of lymphoid malignancies

“…10,11 While encouraging responses are often obtained with current treatment modalities, lymphomas are still the sixth-mostcommon cause of cancer deaths in the United States, and diseases such as low-grade non-Hodgkin lymphomas (NHLs) and chronic lymphocytic leukemia (CLL) remain incurable at present. [12][13][14][15] Lymphomagenesis is often initiated and characterized by specific chromosomal rearrangements. These cytogenetic abnormalities, such as the t (8:14) and t(14:18) chromosome translocations, juxtapose oncogenes (c-myc and bcl-2 principally) to immunoglobulin enhancers and result in the deregulation of their expression.…”

The Low-Grade Lymphoproliferative Disorders

“…The proportion of the various cell types present in the lymphoma serves as the basis for subclassification in follicle center lymphomas. It was shown however that, due to the subjective method of division (estimated per centage of cells and growth pattern), lymphomas are wrongly classified in 24% of cases [68], Inter-and intraob server differences of up to 50% were demonstrated when pathological slides were reviewed. Immunophenotyping by flow cytometry is considered useful and sometimes essential for accurate distinction from the other LGLPD (table 6).…”